Novartis’ $100m bet on eczema drug fails as MOR106 development endsGalapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in Share XNovartis’ $100m bet on eczema drug fails as MOR106 development endshttps://pharmaphorum.com/news/novartis-100m-bet-on-eczema-drug-fails-as-mor106-development-ends/
